A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
Completed · Not applicable
Conditions studied: Cataracts, Meibomian Gland Dysfunction (MGD)
In brief
This is a post-market, prospective, randomized, multi-center, bilateral, open-label, cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow treatment and Control group will not receive preoperative LipiFlow treatment. Three months postoperatively, both groups will be evaluated for clinical outcomes and the Control group will receive LipiFlow treatment as the cross-over group. The Control group will be evaluated at 4 months postoperative for clinical outcomes.
Key facts
- Study ID
- NCT03708367
- Run by
- Johnson & Johnson Surgical Vision, Inc.
- People needed
- 117
- Starts
- 2018-10-16
- Expected to finish
- 2020-01-13
- Last updated by the study team
- 2021-04-27
Who can join
Age: 22 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Empire Eye & Laser Center, Inc. — Bakersfield, California, United States
- Eye Doctors of Washington — Chevy Chase, Maryland, United States
- Matossian Eye Associates — Pennington, New Jersey, United States
- JW Eye Associates, P.A. — Dallas, Texas, United States
- Texas Eye & Laser Center, P.A. — Hurst, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.